Enanta Pharmaceuticals, Inc. operates primarily in the research and development of oral small molecule drugs targeting virology and immunology indications. The company's clinical pipeline is heavily focused on respiratory syncytial virus (RSV), with candidates like zelicapavir and EDP-323 in Phase 2 development, as well as treatments for human coronaviruses and hepatitis B virus (HBV). In addition to its virology programs, Enanta is advancing an earlier-stage immunology pipeline aimed at inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT, STAT6, and MRGPRX2 inhibition. Historically, the company achieved significant success through a collaboration with AbbVie, discovering the protease inhibitors glecaprevir and paritaprevir, which generate ongoing royalty revenues from the sales of HCV cures MAVYRET and VIEKIRA PAK. Enanta does not manufacture or commercialize its own products, relying instead on strategic partnerships and out-licensing agreements for late-stage development and global distribution.
